Luciana L Molinero (Luciana Molinero)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 8

Top Topics

Machine Learning

Decision Making

Newly Diagnosed

Immune Response

Top Venues

The Journal of pathology

JCO precision oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Xiao Li, Jeffrey Eastham, Jennifer M Giltnane, Wei Zou, Andries Zijlstra, Evgeniy Tabatsky, Romain Banchereau, Ching-Wei Chang, Barzin Y Nabet, Namrata S Patil, Luciana L Molinero, Steve Chui, Maureen Harryman, Shari Lau, Linda Rangell, Yannick Waumans, Mark M Kockx, Darya Orlova, Hartmut Koeppen
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. The Journal of pathology (2024)
Xiao Li, Jeffrey Eastham, Jennifer M Giltnane, Wei Zou, Andries Zijlstra, Evgeniy Tabatsky, Romain Banchereau, Ching-Wei Chang, Barzin Y Nabet, Namrata S Patil, Luciana L Molinero, Steve Chui, Maureen Harryman, Shari Lau, Linda Rangell, Yannick Waumans, Mark M Kockx, Darya Orlova, Hartmut Koeppen
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. The Journal of pathology 263 (2) (2024)
Xiao Li, Jeffrey Eastham, Jennifer M Giltnane, Wei Zou, Andries Zijlstra, Evgeniy Tabatsky, Romain Banchereau, Ching-Wei Chang, Barzin Y Nabet, Namrata S Patil, Luciana L Molinero, Steve Chui, Maureen Harryman, Shari Lau, Linda Rangell, Yannick Waumans, Mark M Kockx, Darya Orlova, Hartmut Koeppen
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. The Journal of pathology 263 (2) (2024)
Xiao Li, Jeffrey Eastham, Jennifer M Giltnane, Wei Zou, Andries Zijlstra, Evgeniy Tabatsky, Romain Banchereau, Ching-Wei Chang, Barzin Y Nabet, Namrata S Patil, Luciana L Molinero, Steve Chui, Maureen Harryman, Shari Lau, Linda Rangell, Yannick Waumans, Mark M Kockx, Darya Orlova, Hartmut Koeppen
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. The Journal of pathology 263 (2) (2024)
Charles N Landen, Luciana L Molinero, Habib Hamidi, Jalid Sehouli, Austin Miller, Kathleen M Moore, Cagatay Taskıran, Michael A Bookman, Kristina Lindemann, Charles Anderson, Regina Berger, Tashanna Myers, Mario Beiner, Thomas Reid, Els Van Nieuwenhuysen, Andrew Green, Aikou Okamoto, Carol Aghajanian, Premal H Thaker, Stephanie V Blank, Victor K Khor, Ching-Wei Chang, Yvonne G Lin, Sandro Pignata
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ethan S Sokol, Dexter X Jin, Alexander D Fine, Sally E Trabucco, Sophia Maund, Garrett M Frampton, Luciana L Molinero, Emmanuel S Antonarakis
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. JCO precision oncology 6 (2022)
Kathleen M Moore, Michael A Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Maenpaa, Lyndsay Willmott, Nicoletta Colombo, Jessica Thomes-Pepin, Michalis Liontos, Michael A Gold, Yolanda Garcia, Sudarshan K Sharma, Christopher J Darus, Carol Aghajanian, Aikou Okamoto, Xiaohua Wu, Rustem Safin, Fan Wu, Luciana L Molinero, Vidya Maiya, Victor K Khor, Yvonne G Lin, Sandro Pignata
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (17) (2021)
César Evaristo, Stefani Spranger, Sarah E Barnes, Michelle L Miller, Luciana L Molinero, Frederick L Locke, Thomas F Gajewski, Maria-Luisa Alegre
Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection. Journal of immunology (Baltimore, Md. : 1950) 196 (7) (2016)